Clarity Pharmaceuticals Ltd (ASX:CU6)
Australia
· Delayed Price · Currency is AUD 3.040
0.00 (0.00%)
At close: Dec 5, 2025
Clarity Pharmaceuticals Revenue
In the fiscal year ending June 30, 2025, Clarity Pharmaceuticals had annual revenue of 9.46M AUD, down -17.76%. Clarity Pharmaceuticals had revenue of 4.77M in the half year ending June 30, 2025, with 17.37% growth.
Revenue
9.46M
Revenue Growth
-17.76%
P/S Ratio
119.52
Revenue / Employee
137.14K
Employees
69
Market Cap
1.13B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 23.73B |
| Pro Medicus | 212.98M |
| Cochlear | 2.34B |
| Sonic Healthcare | 9.65B |
| Ramsay Health Care | 17.79B |
| Ansell | 3.06B |
| Telix Pharmaceuticals | 1.01B |
| Mesoblast | 26.23M |
Clarity Pharmaceuticals News
- 7 weeks ago - Clarity Pharma Co-PSMA Trial Meets Main Goal, Detects More Prostate Cancer Lesions Than Standard One - Nasdaq
- 4 months ago - Greatland Resources, Clarity Pharma headline huge ASX 200 rebalance - The Australian Financial Review
- 4 months ago - Clarity Pharmaceuticals readies mega capital raising - The Australian Financial Review
- 1 year ago - Indoco Remedies stock surges 8% on partnership with Clarity Pharma in the UK - Business Upturn
- 1 year ago - Indoco Remedies partners with Clarity Pharma to strengthen UK presence - Business Upturn
- 1 year ago - Rising Shares at Clarity Pharmaceuticals as it Launches Second Phase III Trial and Promotes Michelle Parker to CEO - CEOWORLD magazine
- 1 year ago - Three ASX companies jockeying to be the next biotech winners - The Australian Financial Review